Pinealon vs Selank.

Pinealon is a synthetic ultrashort tripeptide with the sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, abbreviated EDR). It belongs to the class of "peptide bioregulators" developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, who designed short peptides intended to mirror regulatory sequences associated with the pineal gland. It is a research chemical, not an approved drug.

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, with the laboratory designation TP-7. It is a stabilized analog of tuftsin, an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of immunoglobulin G; the added Pro-Gly-Pro tail confers resistance to enzymatic degradation. It is studied primarily as an anxiolytic and nootropic agent and is most associated with Russian neuropharmacology research.

The proposed mechanism, advanced primarily by the Khavinson group, is that short peptides like EDR penetrate cell and nuclear membranes and interact directly with DNA and chromatin to act as epigenetic modulators of gene expression and protein synthesis. In cell and biophysical studies the EDR peptide has been reported to bind deoxyribooligonucleotides/DNA and to enter the nucleus of HeLa cells, and proposed downstream effects include reduced reactive oxygen species, modulation of MAPK/ERK signaling, lowered pro-apoptotic markers (caspase-3, p53), increased antioxidant enzymes (SOD2, GPX1), and stimulation of serotonin-related (tryptophan hydroxylase) expression in cortical neurons. These are mechanistic hypotheses derived largely from in vitro and computational/biophysical work rather than from established receptor pharmacology.

Selank's parent peptide tuftsin acts on immune cells, and Selank retains immunomodulatory activity while shifting toward neuromodulation. Proposed central mechanisms include modulation of monoamine systems (serotonin, dopamine, noradrenaline) and interaction with the GABAergic and enkephalin/opioid systems; Selank has been reported to inhibit enkephalin-degrading enzymes, prolonging the action of endogenous enkephalins. It has also been reported to influence expression of brain-derived neurotrophic factor (BDNF) and to alter cytokine balance (e.g., IL-6 and interferon-related signaling). These mechanisms are largely characterized in rodent and in vitro models rather than established in humans.

There are no completed human efficacy trials of pinealon; the evidence base is preclinical (in vitro cell culture, biophysical, and rodent) and clusters heavily around a single research lineage. Reported findings include increased neuronal cell viability and suppression of free radicals in culture (Khavinson, Rejuvenation Research 2011), nuclear penetration and DNA binding of fluorescently labeled short peptides (Fedoreyeva, Biochemistry Moscow 2011), stimulation of serotonin expression in brain cortex cells (Khavinson, Bull Exp Biol Med 2014), and antioxidant/neuroprotective effects in aged-rat hypoxia and carotid-occlusion models (Mendzheritsky, Adv Gerontol 2011, 2014). A 2020 Molecules review by the developers frames EDR as a candidate neuroprotective agent for early Alzheimer's disease, but it is a hypothesis-generating review of the group's own animal and in vitro data, not clinical proof. Independent, non-affiliated replication is essentially absent, so reported effects should be treated as preliminary.

The great majority of Selank evidence is preclinical (rodent and in vitro), covering anxiolytic-like behavior, stress models, immune/cytokine modulation, and tissue effects under chronic stress (e.g., Bull Exp Biol Med studies on rat intestine and liver under restraint/foot-shock stress, and a cytokine study under 'social' stress). Human clinical data are limited and come almost entirely from Russian-language trials and registry approval rather than large, independently replicated, placebo-controlled studies indexed in Western literature; reported uses include generalized anxiety disorder and asthenic/neurasthenic conditions. A frequently cited molecular review (Protein and Peptide Letters, 2018, PMID 30255741) summarizes the proposed biology. Overall, robust, independently replicated human efficacy data are thin, and mechanistic plausibility should not be read as proven clinical benefit.

Documented safety data in humans are effectively nonexistent; there are no published controlled human safety or pharmacokinetic trials, and no established toxicology dossier in the peer-reviewed literature. Materials sold as "pinealon" are research chemicals not manufactured to pharmaceutical GMP standards, so identity, purity, sterility, and endotoxin content are unverified and vary by vendor. Long-term effects, immunogenicity, and any consequences of the proposed DNA-interacting mechanism are unstudied in humans. Because the compound is unapproved and unregulated for human use, its risk profile is genuinely unknown rather than established as safe.

Published reports, mostly from the developing Russian groups, describe Selank as generally well tolerated with a notably low sedation, dependence, and withdrawal profile compared with benzodiazepines, but rigorous long-term and large-sample safety data from independent groups are lacking. Because much of the safety record comes from the originating institutions and small studies, the true adverse-event and long-term safety profile in humans is not well established. As a peptide typically administered intranasally in research, purity, contamination, and product-quality concerns apply to non-pharmaceutical material. It has not undergone the comprehensive safety review required for major regulatory approval outside its country of origin.

Pinealon is not approved by the FDA or, to public knowledge, any major regulatory authority; it has no ATC code and no standard pharmaceutical identifiers (DrugBank/KEGG/UNII), and is sold only as a research-use-only chemical. It is not a recognized therapeutic and is not WADA-listed as a named substance, though related growth/peptide categories may fall under broader anti-doping provisions.

Selank is reported to have been registered/approved in Russia (around 2009) for anxiety and asthenic conditions, marketed as an intranasal preparation. It is not approved by the US FDA and is not an approved drug in the EU; outside Russia it is effectively investigational and is widely sold as a research-use-only / not-for-human-consumption chemical. It is not a controlled substance and is not a standard WADA-prohibited agent, but its unapproved status means quality and legality vary by jurisdiction.